Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others

Allogene Therapeutics, Inc.

Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.
If Notch out-licenses Released Targets, Allogene receives percentage of upfront/milestone payments up to a cap and low single-digit royalties.
Allogene made ~$22.7M total equity investments in Notch ($5M seed, $15.9M Series A, $1.8M common) and holds ~23% voting interest.
Amended Agreement includes anti-dilution protections for Allogene's stake in Notch for certain pre-IPO equity financings.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Allogene Therapeutics, Inc. amended Amended and Restated Collaboration and License Agreement with Notch Therapeutics, Inc. valued at Amended and restated collaboration and license agreement; company relinquished exclusive rights to o (effective 2024-01-25).

Action: amendment
Agreement: license
Counterparty: Notch Therapeutics, Inc.
Value: Amended and restated collaboration and license agreement; company relinquished exclusive rights to o
Effective: 2024-01-25

Exact text from the filing

On January 25, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Collaboration and License Agreement (the “Amended Agreement”) with Notch Therapeutics, Inc. (“Notch”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.